Literature DB >> 6666229

Hemodynamic effects of isosorbide-5-mononitrate in acute and chronic treatment of coronary heart disease.

P Schuster, G Trieb, H W Wiechmann.   

Abstract

Hemodynamic effects of isosorbide-5-mononitrate (IS-5-MN) were studied in 20 patients with coronary heart disease. Three hours after the first administration of 50 mg IS-5-MN we found a significant decrease in mean pulmonary artery pressure, while heart rate and arterial blood pressure remained unchanged. Concomitant with the hemodynamic effects we found a decrease in angina pectoris and normalization of exercise-induced ST depression. After 50 mg IS-5-MN three times daily for 1 week the repeated acute administration of a single dose of 50 mg produced a fall in mean pulmonary artery pressure at rest (-25%) and during exercise (-20%), while the antianginal effect was unchanged. Six hours after a repeated single dose we found no change in hemodynamic parameters as compared with the control levels before treatment. The decreased effect on the pulmonary artery pressure under chronic treatment is discussed as a development of tolerance with decrease of venous pooling. The unchanged antianginal effect is difficult to understand, and may be interpreted as due to an influence on the coronary vessels and collateral blood flow.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6666229

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  3 in total

Review 1.  An update on nitrate tolerance: can it be avoided?

Authors:  S R Maxwell; M J Kendall
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

Review 2.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Lack of effect of asymmetrical dosage timing of isosorbide-5-mononitrate on nitrate tolerance during long-term administration.

Authors:  L O Hughes; P DasGupta; D Jain; A Lahiri; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.